Portfolio Building Block World Pharma and Biotech Index ETF (PBPH)

The Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) tracks global companies engaged in the discovery, development, and commercialization of human therapeutics. Launched in November 2025 by Tidal Investments, the fund offers systematic exposure to the worldwide pharmaceutical and biotechnology industries.

The evolution of pharmaceutical and biotech industries

The pharmaceutical industry emerged in its modern form in the late nineteenth and early twentieth centuries, as chemists learned to synthesize and purify compounds at scale and physicians began systematically testing them in patients. The biotechnology industry is younger, arising in the 1970s and 1980s as advances in genetic engineering and molecular biology enabled companies to use living cells and organisms to manufacture proteins and design entirely novel therapeutics.

Both industries are fundamentally dependent on innovation and intellectual property. A successful drug is protected by patents and regulatory exclusivity periods that can last 15 to 20 years, during which the company that developed it can charge premium prices with limited direct competition. Once patents expire, generic and biosimilar versions flood the market, and the company must rely on newly developed products to replace lost revenue. This cycle of innovation, patent protection, and expiration drives the economics of both sectors.

From blockbuster drugs to personalized medicine

For decades, the pharmaceutical industry was structured around blockbuster drugs—compounds that achieved annual sales of more than one billion dollars and served large patient populations with common diseases such as high cholesterol, hypertension, and arthritis. Companies invested heavily in developing and marketing these molecules, knowing that a single success could fund years of other research.

Over the past 20 years, the industry has shifted toward smaller, more targeted markets. Oncology drugs that work for specific cancer subtypes, rare-disease therapies that serve only thousands of patients, and new modalities such as gene therapy and cell therapy have become proportionally more important. This shift reflects both regulatory demands for better clinical evidence and the reality that most common diseases already have established treatments. Growth now comes from underserved areas, novel mechanisms of action, and precision medicine approaches.

Biotechnology companies have emerged as particular drivers of innovation in these newer areas. Early-stage biotech firms often pioneer new therapeutic approaches and are later acquired by larger pharmaceutical companies or licensed to them. This creates a complex ecosystem where small specialized companies drive scientific advancement while large integrated firms handle development, regulatory approval, manufacturing, and commercialisation.

The current portfolio: scale and diversity

PBPH holds approximately 57 securities that meet the fund’s inclusion criteria—companies deriving a significant portion of revenues from therapeutic discovery, development, and commercialization. The largest positions are integrated pharmaceutical firms with substantial market capitalisation and long product histories: Eli Lilly and Company (specialising in metabolic disease and oncology), Johnson & Johnson (consumer health, pharmaceuticals, and medical devices), AbbVie (immunology and virology), Roche (diagnostics, oncology, and immunology), and Novartis (oncology, immunology, and rare disease).

Beyond the top tier, PBPH includes hundreds of smaller pharmaceutical and biotech companies, many of which do not yet generate revenue from approved drugs but instead pursue development programs in early or middle stages of clinical testing. This mixture of stable, profitable incumbents and higher-risk development-stage firms means PBPH captures both the predictable cash generation of established drugs and the growth potential of emerging therapies.

Current challenges and structural pressures

The industry today faces several headwinds that shape the investment case. Regulatory requirements for clinical evidence have become more stringent, requiring larger and longer trials to demonstrate safety and efficacy. Patent cliffs continue as drugs lose exclusivity, creating revenue pressure that companies must offset with new approvals. Pricing scrutiny has intensified: governments and insurance payers in developed countries increasingly demand discounts on pharmaceutical prices, constraining margin expansion.

Additionally, the cost of bringing a new drug to market has risen substantially, now estimated at several billion dollars when accounting for failures. Biotechnology companies that pursue high-risk therapeutic approaches can face binary outcomes where a single failed trial destroys value. Success requires not only scientific insight but also capital discipline, regulatory expertise, and the ability to navigate a complex global approval landscape.

For researchers and investors

Investors studying PBPH should begin with the fund’s prospectus and current holdings list to understand the exact portfolio composition. The annual reports and 10-K filings of the largest positions offer insight into research pipelines, recent drug approvals, and strategic priorities. Tracking the FDA approval calendar and clinical-trial results from major companies provides real-time context for understanding whether the fund’s constituents are advancing new therapies successfully. Industry publications such as those from Evaluate Pharma, Fierce Pharma, and similar sources track sector trends, patent expirations, and emerging therapeutic areas where capital is flowing.